CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L. Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S. Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.

Translated title of the contributionCXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen
Original languageEnglish
Pages (from-to)57-61
Number of pages5
Issue number2
StatePublished - 9 Aug 2023
Externally publishedYes


  • CXCR4
  • T-cell lymphoma
  • [68Ga]Ga-PentixaFor
  • chemokine receptor
  • marginal zone lymphoma
  • theranostics


Dive into the research topics of 'CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges'. Together they form a unique fingerprint.

Cite this